The role of preclinical animal models in breast cancer drug development

Breast Cancer Research

Volumn 11, Issue SUPPL. 3, 2009, Pages

  Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY SURFACE; BREAST CANCER; CLINICAL TRIAL (TOPIC); DNA REPLICATION; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; NONHUMAN; RISK ASSESSMENT; SENSITIVITY ANALYSIS; ANIMAL; BREAST TUMOR; DISEASE MODEL; DRUG DESIGN; DRUG INDUSTRY; DRUG SCREENING; FEMALE; METHODOLOGY;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; FEMALE; HUMANS;

EID: 77951889025     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2441     Document Type: Article

References (25)

1. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet 1998, 352:930-942. 10.1016/S0140-6736(98)03301-7, 9752815, Early Breast Cancer Trialists' Collaborative Group.
2. Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JL, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen-receptor-negative tumors: eight year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996, 14:1982-1992.
3. Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, Falkson G. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis - an intergroup study. J Clin Oncol 1998, 16:3486-3492.
4. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998, 351:1451-1467. 10.1016/S0140-6736(97)11423-4, 9605801, Early Breast Cancer Trialists' Collaborative Group.
5. Early Breast Cancer Trialists Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992, 399:1-15. Early Breast Cancer Trialists Collaborative Group.
6. Rosen PR, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989, 7:355-366.
7. Hellman S, Harris JR. Natural history of breast cancer. Disease of the Breast 2000, 407-423. Philadelphia: Lippincott-Raven, Harris J, Lippman ME, Morrow M, Osborne CK.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
9. Zhang Y, Soumerai SB. Do newer prescription drugs pay for themselves? A reassessment of the evidence. Health Aff (Millwood) 2007, 26:880-886. 10.1377/hlthaff.26.3.880, 17485770.
10. Baker D, Fugh-Berman A. Do new drugs increase life expectancy? A critique of a Manhattan institute paper. J Gen Intern Med 2009, 24:678-682. 2669876, 19308335, 10.1007/s11606-009-0954-4.
11. Clarke R, Ressom HW, Wang A, Xuan J, Liu MC, Gehan EA, Wang Y. The properties of very high dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer 2008, 8:37-49. 2238676, 18097463, 10.1038/nrc2294.
12. Drews J. Drug discovery: a historical perspective. Science 2000, 287:1960-1964. 10.1126/science.287.5460.1960, 10720314.
13. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715. 10.1038/nrd1470, 15286737.
14. Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv 2007, 7:325-334. 10.1124/mi.7.6.9, 18199854.
15. Lawson DH. Adverse drug reactions. Hum Toxicol 1985, 4:122-126. 10.1177/096032718500400202, 4007876.
16. Permissible medical experiments. 1949 No. 10: 181-182. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law 2. Washington, DC: US Government Pronting Office.
17. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966, 50:219-244.
18. Clark DL, Andrews PA, Smith DD, DeGeorge JJ, Justice RL, Beitz JG. Predictive value of preclinical toxicology studies for platinum anticancer drugs. Clin Cancer Res 1999, 5:1161-1167.
19. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004, 3:226-236. 10.1038/nrd1329, 15031736.
20. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van DK, Smith P, Berger B, Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000, 32:56-67. 10.1006/rtph.2000.1399, 11029269.
21. Clarke R. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 1996, 39:69-86. 10.1007/BF01806079, 8738607.
22. Clarke R. Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Res Treat 1997, 46:255-278. 10.1023/A:1005938428456, 9478280.
23. Clarke R, Johnson MD. Animal models. Diseases of the Breast 2000, 319-333. Philadelphia: Lippincott, Harris JR, Lippman ME, Morrow M, Hellman S.
24. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001, 53:25-71.
25. Fugh-Berman A, Melnick D. Off-label promotion, on-target sales. PLoS Med 2008, 5:e210. 2573913, 18959472, 10.1371/journal.pmed.0050210.